| Bringing the Single-Vendor Approach to the Pharma Industry |
| |
| As drug developers face increasing pressure to get their products to market as quickly as possible, read an economist’s viewpoint of how single-source networks cut development timelines. |
| |
 |
| |
Read this 1 page interview with Robert Fry
Chief Economist Robert Fry economics LLC |
|
|
|
| Smaller Biotech Companies and the Single-Source CDMO |
| |
| A single-source CDMO that manages the end-to-end relationship with pharmaceutical clients can bring many efficiencies to the development process. Learn why smaller companies, in particular, may benefit from working with a large, single-source vendor. |
| |
|
| |
Read this 1 page interview with Dr. Doug Johnson
PHD founder of OCAM Solutions |
|
|
